In 2019, the American College of Veterinary Internal Medicine (ACVIM) updated their consensus guidelines for the diagnosis and treatment of mitral valve disease in dogs1.
The new guidelines for treatment of CHF include spironolactone to help mitigate the effects of the renin-angiotensin-aldosterone system (RAAS). This standard has become known as Quad Therapy.
The combination of Benazepril and Spironolactone in CARDALIS™ provides a unique combination of active ingredients to block the effects of the RAAS cascade. These active ingredients are recommended by the ACVIM to treat CHF at the onset of signs.
Learn more by visiting: Cardalis for Dogs
- Keene et al. 2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 33(3):1127-1140.